Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 10, 2015, Pages 2838-2843

  Ferro, Beatriz E ^a   van Ingen, Jakko ^a   Wattenberg, Melanie ^a   van Soolingen, Dick ^a,b   Mouton, Johan W ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLARITHROMYCIN; MOXIFLOXACIN; ANTIINFECTIVE AGENT;

ABSORPTION LAG TIME; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL KINETICS; BROTH DILUTION; COLONY FORMING UNIT; EC50; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM HOMINISSUIS; MYCOBACTERIUM XENOPEI; NONHUMAN; ANTIBIOTIC RESISTANCE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION; TIME FACTOR;

AMIKACIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTATION RATE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM XENOPI; TIME FACTORS;

EID: 84943743850     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv180     Document Type: Article

References (18)

1. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculousmycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
2. Hoefsloot W, van Ingen J, Andréjak C et al. The geographic diversity of non-tuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Resp J 2013; 42: 1604-13.
3. Andréjak C, Lescure FX, Pukenyte E et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009; 64: 291-6.
4. van Ingen J, Ferro BE, Hoefsloot Wet al. Drug treatment of pulmonary antituberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther 2013; 11: 1065-77.
5. Andréjak C, Almeida DV, Tyagi S et al. Improving existing tools for Mycobacterium xenopi treatment assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother 2013; 68: 659-65.
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
7. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actynomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
8. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19: 355-8.
9. de Steenwinkel JEM, de Knegt GJ, ten Kate MT et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 2582-9.
10. Donald PR, Sirgel FA, Venter A et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2001; 5: 533-8.
11. Bakker-Woudenberg IAJM, van Vianen W, van Soolingen D et al. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. Antimicrob Agents Chemother 2005; 49: 2387-98.
12. Ferro BE, van Ingen J, Wattenberg M et al. Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. J Antimicrob Chemother 2015; 70: 811-7.
13. van Ingen J, Egelund EF, Levin A et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012; 186: 559-65.
14. Davis KK, Kao PN, Jacobs SS et al. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007; 23: 2.
15. Olivier KN, Shaw PA, Glaser TS et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014; 11: 30-5.
16. van Ingen J, Boeree MJ, van Soolingen D et al. Resistance mechanisms and drug susceptibility testing of nontuberculosis mycobacteria. Drug Resist Updat 2012; 15: 149-61.
17. van Ingen J, HoefslootW, Mouton JWet al. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculousmycobacteria is currently of questionable clinical significance. Int J Antimicrob Agents 2013; 42: 80-2.
18. van Ingen J, Boeree MJ, de Lange WC et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infec Dis 2008; 14: 385-9.